kinesin family member 20AGenealiases: MKLP2 · RAB6KIFL · RCM6
Q-omics provides the consensus-scored KIF20A profile across patient tissues and cancer cell-line models. KIF20A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KIF20A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KIF20A RNA expression shows 25,134 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where KIF20A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF20A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF20A survival associations across molecular data types. KIF20A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF20A RNA expression–survival associations across cancer types. High KIF20A expression shows unfavorable associations in KIRP, ACC, MESO, LIHC, UVM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KIF20A RNA expression.
This table summarizes KIF20A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF20A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF20A shows higher tumor expression in HNSC, KIRC, BLCA, KIRP, LUAD and COAD. The HNSC box plot shows higher KIF20A RNA expression in tumor versus normal tissue (log2 FC = +2.051, t-test p < 0.001).
This table shows molecular features associated with KIF20A in patient tissues and cancer cell lines. In patient samples, KIF20A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF20A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
